Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex (Nasdaq: ENLV) approved a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026, when trading will begin on a split-adjusted basis.
Authorized shares decrease from 2,375,000,000 to 158,333,334, outstanding shares to about 16,832,015, with unchanged ownership percentages and voting rights.
Enlivex (Nasdaq: ENLV) announced that its primary treasury asset, the RAIN token, is expected to list on the Gate cryptocurrency exchange on June 24, 2026 at 10:00 AM UTC. Gate is described as serving over 54 million users and ranking second globally in 24-hour spot trading volume.
Enlivex focuses its digital treasury strategy on acquiring RAIN. As of June 21, 2026, it reportedly held 79,568,550,005 RAIN valued at approximately $1.14 billion, implying a treasury NAV per share of $4.67. The listing is expected to broaden access and secondary liquidity for RAIN.
Enlivex (Nasdaq: ENLV) reported updated treasury metrics tied to its RAIN token holdings. As of June 20, 2026, Enlivex held 79,568,550,005 RAIN tokens valued at approximately $1.14 billion. Treasury NAV per Share was $4.671, based on current RAIN holdings and ordinary shares outstanding.
Enlivex (Nasdaq: ENLV) announced issuance of Australian patent 2020340629 covering methods of using Allocetra™ to treat osteoarthritis. The patent provides protection in Australia through at least 2040, expanding Allocetra’s osteoarthritis IP coverage as a Phase 2b knee osteoarthritis trial advances with the first U.S. patient dosed.
Enlivex (Nasdaq: ENLV) announced it is a Gold Sponsor of Proof of Talk 2026, held June 2-3, 2026 at the Louvre Palace and Musée des Arts Décoratifs in Paris.
CEO Dr. Oren Hershkovitz will present Enlivex's quality longevity model powered by a prediction markets treasury at a curated institutional investor dinner.
Enlivex (Nasdaq: ENLV) reported extended 3- and 6-month data from its Phase IIa trial of Allocetra in moderate-to-severe knee osteoarthritis. Allocetra showed clinically meaningful, statistically significant pain reduction and functional improvement versus placebo in idiopathic age-related patients ≥60, a group representing over 50% of the KOA market.
The data, highlighting Allocetra’s novel immunomodulating mechanism, were selected for an oral presentation at EULAR 2026 on June 3, 2026. Enlivex said these results supported progression into an ongoing Phase IIb study, where the first US patient was recently dosed.
Enlivex (Nasdaq: ENLV) reported holding 79,568,550,005 RAIN tokens valued at approximately $1.16 billion as of May 27, 2026. The Rain Foundation appointed five crypto and blockchain industry leaders to its advisory board and committed $100 million liquidity to the Rain prediction markets protocol, positioning it as the third-largest prediction market protocol by TVL. Rain's open beta has attracted over 29,000 users and burned more than 100 million RAIN tokens, supporting Enlivex’s view of RAIN as a core treasury asset.
Enlivex (Nasdaq: ENLV) reported updated exposure to the Rain prediction markets protocol treasury.
As of May 26, 2026, Enlivex held about 79.6 billion RAIN tokens valued near $919 million and an option on up to 271.4 billion additional tokens, while Rain received a $100 million liquidity commitment that positions it among the top three global prediction markets by TVL.
Enlivex (Nasdaq: ENLV) dosed the first U.S. patient in its global, randomized, double-blind, placebo-controlled Phase 2b trial of Allocetra for moderate-to-severe age-related primary knee osteoarthritis.
The study spans the United States, Denmark and Poland, with endpoints focused on pain, function, quality of life and mobility.
Enlivex (Nasdaq: ENLV) received a Nasdaq notice that its ordinary shares failed to meet the $1.00 minimum bid price for 30 consecutive business days, triggering a compliance period.
Enlivex has 180 days, until November 9, 2026, to regain compliance, with a possible additional 180-day extension.